What is the epitalon dosage?

There is no approved or established epitalon dose. The only human trial used 0.5 mg/day as a sublingual spray for 20 days in 40 women, and measured a melatonin metabolite rather than any clinical outcome. Injection protocols sold online are not from a human study — the FDA found no study of injected epitalon in people.

Does epitalon lengthen telomeres?

In a dish, yes: human fetal fibroblasts exposed to 50 ng/mL for four days showed telomerase induction and longer telomeres. No study has shown that in a living person. The FDA also noted a theoretical cancer concern with sustained telomerase activation.

Is epitalon FDA approved?

No, and it is not approved in the EU, UK, Canada or Australia either. It was removed from the FDA's Category 2 when its nomination was withdrawn in April 2026; an advisory committee voted in July 2026 to recommend it for the compounding list for insomnia, against FDA staff advice, but it is not on the 503A Bulks List.

Is epitalon the same as epithalamin?

No. Epithalamin is an extract of bovine pineal gland; epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly. The FDA treats them as different substances, and evidence for one does not transfer to the other.

Epitalon Dosage Calculator and Study Dose Chart

A synthetic four-amino-acid peptide, not the same thing as the pineal extract epithalamin. Almost all of its data comes from one research group, and its only human trial measured a melatonin metabolite.

Written by Kashif Khan, who builds and maintains this site and is not a clinician. Every figure links to its primary source.

Not approved

Not approved anywhere; not on the 503A Bulks List

The FDA states that epitalon (the synthetic tetrapeptide) and epithalamin (a bovine pineal extract) are different substances, and found no approved epitalon product in the EU, UK, Canada or Australia. Epitalon sat in Category 2 until its nomination was withdrawn on 22 April 2026. In July 2026 the FDA reviewed it for insomnia and its staff recommended against inclusion; the advisory committee voted in favour, which is non-binding, and epitalon is not on the 503A Bulks List.

No approved human dose exists for this compound in any country. The figures below are the doses used in named published studies, reproduced for reference only. Doses given to rats or mice do not convert to a human dose. The FDA has stated that labelling a product “research use only” or “not for human consumption” does not change its legal status when the seller's own marketing shows it is intended for people.

Calculator inputs

Set up your vial

Enter the label, dilution and dose. The result updates as you type.

Syringe volume

Epitalon in the vial

500 mcg is a calculator example; the only human study was sublingual, not injected

Bacteriostatic water to add

Dose per injection

No approved human dose exists for this compound. The dose shown is only a calculator input, not a recommendation or starting point.

More optionsReverse calculation, schedule and cost

Enter the bacteriostatic water you added and get the volume to draw.

Injections per week

Discard afterdays

Vial priceoptional

Draw to

10units(0.1 mL)

Concentration: 5000 mcg/mL
Water added: 2 mL
Doses in vial: 20

How the concentration is calculated

This divides the peptide by the water you add. The powder occupies a little volume of its own, which is negligible on a typical vial but not on one with a heavy bulking agent. When a product label states a concentration, use the label’s number.

Key facts

Molecular weight: 390.35 DaAla-Glu-Asp-Gly, C14H22N4O9.
Half-life: Not published. No accessible human pharmacokinetic study reports one, so any specific figure quoted elsewhere has no primary source behind it.
Also sold as: Epithalon, AEDG, Ala-Glu-Asp-Gly, epithalone

Doses used in published studies

These are reproduced for reference. They are not recommendations, and an animal dose in mg/kg does not convert to a human dose.

humansublingual spray, twice daily

0.5 mg/day for 20 days

Ivko et al., 2020: 40 women aged 40–50 working night shifts, randomized to AEDG or placebo. Urinary 6-sulfatoxymelatonin rose 1.7-fold. The FDA notes blinding was not specified and the spray volume was not described.

mousesubcutaneous

1.0 µg per mouse on 5 consecutive days each month, from 3 months of age until death

Anisimov et al., 2003, female SHR mice (54 per group): mean lifespan did not change; the longest-lived 10% lived 13.3% longer and leukaemia incidence fell. One strain, one sex, one dose.

How good is the evidence?

Thin and concentrated in one place. The FDA notes that nearly all epitalon research comes from the St Petersburg Institute of Bioregulation and Gerontology and its collaborators, with little independent replication. The only randomized human study gave 0.5 mg/day sublingually to 40 women for 20 days and measured a melatonin metabolite in urine, not sleep. No human study used injection, no pharmacokinetic study exists beyond a rabbit distribution study, and much of the human evidence quoted online is actually about epithalamin.

Epitalon is not epithalamin

The distinction decides what evidence counts. Epithalamin is a polypeptide complex extracted from bovine pineal glands; epitalon is a four-amino-acid peptide, Ala-Glu-Asp-Gly, synthesised to mimic part of it. The FDA treats them as different substances, and so should anyone reading a claim: many of the human ageing studies cited for epitalon gave epithalamin, a different product, often by a different route.

What the studies actually show

The telomerase claim comes from cell culture: in human fetal fibroblasts, epitalon at 50 ng/mL for 4 days induced telomerase and lengthened telomeres. The lifespan claim comes from mice: subcutaneous injections did not extend average lifespan, though the longest-lived mice lived somewhat longer. The single randomized human trial measured a melatonin breakdown product after 20 days of a sublingual spray.

None of that is a human injection dose. The FDA found no human study using subcutaneous injection — the route proposed for compounding — no clinical study for insomnia, and no published half-life. It also raised a theoretical concern that sustained telomerase activation could promote cancer, which no study has been designed to answer.

Common questions

Sources

Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.

RegulatorFDA· 2026-07
FDA evaluation of epitalon for the 503A Bulks List — PCAC briefing document, July 2026
RegulatorFDA· 2026-07
July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
RegulatorFDA
Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
ReferenceNCBI PubChem
Epitalon (Ala-Glu-Asp-Gly) — PubChem compound summary (CID 219042)
Published study· 2020
Ivko OM et al. AEDG peptide regulates human circadian rhythms genes expression during pineal gland accelerated aging (Russian). Adv Gerontol 2020
Published study· 2003
Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003
Published study· 2003
Khavinson VKh et al. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003